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Systems biology aims to provide a holistic and in many cases dynamic picture of biological function and
malfunction, in case of disease. Technology developments in the generation of genome-wide datasets and
massive improvements in computer power now allow to obtain new insights into complex biological net-
works and to copy nature by computing these interactions and their kinetics and by generating in silico
models of cells, tissues and organs. The expectations are high that systems biology will pave the way to
the identiﬁcation of novel disease genes, to the selection of successful drug candidates—that do not fail in
clinical studies due to toxicity or lack of human efﬁcacy—and ﬁnally to a more successful discovery of
novel therapeutics. However, further research is necessary to fully unleash the potential of systems biol-
ogy. Within this review we aim to highlight the most important and promising top-down and bottom-up
systems biology applications in drug discovery.
 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.Biological functionality—like the secretion of insulin from the
pancreatic beta cell to control blood glucose or the contraction of
cardiomyocytes to pace the rhythm of the heart beat—emerges
from interactions among several hundred genes and proteins with-
in the cellular environment. In order to understand living cells,
understanding these networks, identifying the most important
nodes and their connections, appears to be a pre-requisite.1
From a reductionist view to a systems view. In the last decades,
drug discovery has been dominated by reductionism aiming to
identify drugs that activate or inhibit speciﬁc molecular (disease)
targets. However, biology is complex and it is increasingly clear
that a discrete biological function—or malfunction in case of a dis-
ease—can rarely be attributed to an individual protein or gene. It
also has become evident that recombinant cell lines over-express-
ing the single disease target that are used in screening approaches
are often insufﬁcient surrogates for the biology of primary cells or
tissue. As a consequence drug molecules propagated by this sim-
plistic view either often showed unforeseen toxicity or lack of efﬁ-
cacy when tested in humans in clinical trials.2 Nowadays, disease is
not seen any longer as a failure of a single gene or target, but is
viewed as a consequence of disease-perturbed networks. The anal-
ysis of transcriptomics or proteomics data of individual patient tis-
sues can provide insights into the ‘signature’ of the disease
phenotype. The objective of a successful drug treatment would
then be the reversal of the disease signature to normal.
Systems biology approaches attempt to provide a more holistic
and in many cases dynamic picture of biological processes. It is all
about understanding biology in a context to address the right tar-gets and the right biological mechanism by a pharmacological
treatment. Technology developments in the area of, for example,
next generation sequencing (NGS), transcriptomics, metabolomics
and (phospho)proteomics enable parallel and high throughput
characterization of biological systems. The available massive
improvements in computer power allow the analysis of these gen-
ome-wide data sets to derive complex network views of biological
systems and to infer the logic behind a biological function or mal-
function. The computational improvements also allow copying
nature by computing these interactions and their kinetics and by
generating in silico models of cells, tissues and organs.
Top-down versus bottom-up system biology approaches. As out-
lined in Figure 1 scientists classify systems biology approaches into
‘top down’ and ‘bottom-up’ methods.
Top-down systems biology approaches attempt to identify the
networks and the logic behind a biological function by the analysis
of genome-wide data sets. In other words, these approaches start
with a comprehensive set of data generated by one or more of
the ‘omics’ technologies and aim to identify networks and compo-
nents that are participating in the generation of a phenotype or a
disease—often even without the necessity of prior knowledge. Sci-
entists often refer to these as ‘top-down’ systems biology ap-
proaches. In this class belong gene-set enrichment analysis,
pathway mapping, disease classiﬁcation, reverse causal reasoning
and network inference approaches. From the perspective of drug
discovery, the top-down systems biology methods aim at a deeper
understanding of the causes of a disease, to stratify patients and to
identify the right molecular targets.
Bottom-up systems biology approaches try to copy nature by
generating computational models of cells, tissues and organs. Here,
individual components are assembled into a network with the goal
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Figure 1. Systems biology approaches can be roughly divided into two categories.
Bottom-up methods start from an often detailed knowledge about individual
components and assemble these into larger units (e.g., a pathway) in order to
simulate the behavior of this assembly. Top-down approaches start from data sets
that represent huge parts of a biological system (e.g., transcriptomics data,
interactome data) and try to identify those subnetworks, pathways or components
that are most responsible for the systems behaviour (e.g., a phenotype).
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several biological processes these so-called molecular-mechanistic
models are available, which capture and simulate cellular signal-
ling processes (e.g., virtual heart).3 Only recently a whole-cell com-
putational model of the life cycle of the human pathogen
Mycoplasma genitalium that includes all of its molecular compo-
nents and their interactions has been published.4 The main meth-
ods to turn these static signalling networks into computable
models able to simulate the dynamics of a biological systems are
ODE-based5 or Boolean-logic based modelling.6 Other models do
not provide the molecular mechanistic detail but are more phe-
nomenological in nature and capture the ﬂuxes of the ‘reaction’
partners in the system (e.g., glucose insulin homeostasis). The
objective of these modelling approaches is to shed some light into
signalling processes, to identify and/or validate drug targets using
a holistic and dynamic approach, to provide the key optimization
parameters for a chemical optimization program and ﬁnally to pre-
dict the effect of a drug treatment in virtual patients.
This ‘digest’ will highlight prominent examples of how systems
biology can foster the understanding of cellular systems and hu-
man physiology, how it can provide insights into the logic of a bio-
logical function and/or disease and how these insights can be
applied to the discovery of novel targets and drugs. The next sec-
tion will provide examples on top-down systems biology ap-
proaches, whereas in the last section case studies on bottom-up
systems biology approaches will be given.
One very simplistic answer to the question ‘What is systems
biology?’ is ‘making sense of the omics data’. Although this is a
very simpliﬁed view it deﬁnitely describes the main objective of
top-down systems biology approaches. Over the past years, due
to the low cost of microarray datasets, probably millions of sam-
ples have been characterized for their basal gene expression proﬁle
and for changes in the gene regulation imposed by perturbations
like diseases or drugs. Other ‘omics’ technologies are advancing
and proﬁling data beyond gene expression becomes more and
more available. Modern mass-spectrometry approaches allow
identiﬁcation and quantiﬁcation of several thousands of proteins
in one sample.7 On the other hand typical metabolomics proﬁles
now are able to resolve up to 500 metabolites by LC or GC coupled
to MS/MS providing deep and informative insights. By performing
global metabolite proﬁling, also known as untargeted metabolo-
mics, new discoveries linking cellular pathways to biological
mechanism are being revealed and are shaping our understanding
of cell biology, physiology and medicine.8 And last but not least the
individual genomes—the digital source code of life—are more and
more accessible as next generation sequencing technologies have
delivered on their promise of sequencing DNA at unprecedented
speed.9A signiﬁcant number of recent studies wink at the idea that
every biological state can be described by its speciﬁc gene expres-
sion signature: a well deﬁned set of genes together with a pattern
of expression that is exclusively linked to it. In this scenario micro-
array technology can be deemed as the natural language through
which these ‘biological-state-summaries’ can be generated. Differ-
ent disease-perturbed states are characterized by an expression
signature that can then translate into the same disease phenotype
(e.g., diabetes). This indicates that the one phenotype can have dif-
ferent causes. It is thought that the expression ‘ﬁngerprint’ still
holds more information than the clinical disease phenotype itself,
as it allows to identify the activity of crucial biological pathways
and to correlate these measurements with clinico-pathological fea-
tures. In other words, it can hold the information for understanding
the disease mechanisms and for stratiﬁcation of patients.
Genome-wide data sets covering genotyping, transcriptomics,
(phospho) proteomics and/or metabolomics provide rich sources
of information. Systems biology not only looks into these data sets
at the individual gene level to identify, for example, genes that are
up or down-regulated under a certain condition, but tries to have a
holistic view of this data to understand the mechanism(s) of a dis-
ease phenotype, to pinpoint disease genes, to support patient strat-
iﬁcation and to propose drugs for re-positioning. This is achieved
by the following approaches (see Fig. 2):
 Gene-set enrichment analysis and/or mapping of differentially
regulated genes on pathway maps can identify those gene sets
or pathways that are signiﬁcantly perturbed by, for example, a
disease or drug treatment. This provides an overview of high-
level processes changing upon perturbation of the system.10,11
 Classiﬁcation of diseases for patient stratiﬁcation can be based on
gene expression proﬁles and can be performed directly on the
primary ‘omics’ data12 or based on the strength of so-called sig-
nalling signatures.13
 Reverse causal reasoning (RCR) approaches attempt to identify
the causal drivers of a disease and to understand the ‘logic’
behind the observed changes in a gene expression proﬁle.14–16
 In order to generate new insights into the cellular wiring network
inference approaches can be used.17,18 For example, novel connec-
tions canbe identiﬁedbyusingmicroarraydatasets and capturing
the degree by which each pair of genes is co-expressed (that is,
assigning each pair of genes a correlation coefﬁcient). These gene
co-expression networks can be used to complement the pre-
existing views on metabolic or signalling pathways. Sensitive
nodes within these networks can then qualify as disease targets.
In the following we have selected several case studies to illus-
trate applications in these areas.
Gene-set enrichment analysis and pathway mapping. In systems
biology, gene-set enrichment (GSE) analysis represents one of the
most popular forms to analyze microarray and other high-through-
put data.10 By correlating ranked lists of regulated genes from a
transcriptomics study with pre-deﬁned categories of genes (e.g.,
pathways, biological processes) those pathways and biological pro-
cesses can be identiﬁed that are most signiﬁcantly changed in the
sample studied (e.g., diseased vs healthy). Focusing on sets of genes
rather than on individual genes has several beneﬁts. From a statis-
tical point of view the analysis of groups instead of individual
genes is advantageous as this typically increases power and re-
duces the dimensionality of the underlying statistical problem.
From the biological perspective gene set enrichment analysis al-
lows to ask (and answer!) questions that are of direct interest to
the understanding of the functional mechanism in a cell: is a cer-
tain pathway activated in a given tissue under some treatment X
or state Y? Ackermann & Strimmer give an excellent review of
the many methods proposed.11
Figure 2. Top-down systems biology approaches: analysis of genome-wide data-
sets supports understanding of disease mechanisms, stratiﬁcation of patients,
discovery of novel drugs by repurposing, and identiﬁcation of novel drug targets.
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way mapping, which means that the lists of regulated genes are
projected onto pathway maps for those pathways that have been
identiﬁed by a GSE analysis. Biological pathways have become
the most popular form of representing biochemical information
for hypothesis generation and validation. These maps store wide
knowledge of complex molecular interactions and regulations
occurring in the living organism in a simple and obvious way, often
using intuitive graphical notation. Two major types of biological
pathways can be distinguished. Metabolic pathways incorporate
complex networks of protein-based interactions and modiﬁcations,
while signal transduction and transcriptional regulatory pathways
are usually considered to provide information on mechanisms of
transcription.19 Publicly available pathway databases have been
recently reviewed by Bauer-Mehren et al.20
Gene-set enrichment analysis combined with pathway map-
ping can not only help to pinpoint speciﬁc disease-relevant path-
ways, but also to discover novel disease targets or to generate
hypothesis for drug repurposing. At Sanoﬁ we have, for example,
identiﬁed the mTOR pathway by mapping of differentially regu-
lated genes in old versus young patients from muscle biopsies onto
a database of networks and pathways (see Fig. 3). This led to the
hypothesis that compounds inhibiting mTOR might be used forthe treatment of sarcopenia.21 The study suggested the reposition-
ing of rapamycin, an immunosuppressant drug used to prevent
rejection in organ transplantation. This hypothesis is currently
being tested in a clinical trial that is exploring the use of rapamycin
for this indication.
Classiﬁcation of diseases and stratiﬁcation of patients. Even a pop-
ulation of patients that appears to be phenotypically similar can
exhibit distinct molecular disease proﬁles. For example, in a dis-
ease like atherosclerosis, there are multiple elements that may
contribute. A similar clinical diagnosis, therefore, may be the inte-
grated result of multiple molecular disease-driving mechanisms.
Thus, the patient population in a clinical trial for a targeted therapy
often represents multiple disease data subsets. As each can be dri-
ven by different molecular mechanisms, only a subset will respond
to a very speciﬁc, molecularly-focussed treatment.13
There are several examples of how biomarkers are used to iden-
tify the likely-to-respond subjects, best exempliﬁed in oncology.
Biomarkers can originate from immunohistochemical analysis
(immunohistochemical detection of the estrogen receptor is used
to predict the efﬁcacy of tamoxifen in breast cancer), genotyping
of the tumor sample (e.g., k-ras mutations predict resistance to
anti-EGFR therapy in colon cancer) or detection of gene ampliﬁca-
tion (HER2 gene ampliﬁcation is a positive indication for trast-
uzumab, Herceptin, treatment in breast cancer). Selecting the
patient pool most likely to respond has proven beneﬁcial for
obtaining regulatory approval of effective drugs.
In a landmark paper Golub et al. presented a generic approach
to cancer classiﬁcation based on gene expression monitoring by
DNA microarrays.12 A classiﬁcation procedure automatically dis-
covered the distinction between acute myeloid leukemia (AML)
and acute lymphoblastic leukemia (ALL). The class predictor was
able to determine the class of new leukemia cases (see Fig. 4).
The results demonstrate the feasibility of cancer classiﬁcation
based solely on gene expression monitoring and suggest a general
strategy for discovering and predicting cancer classes for other
types of cancer, independent of previous biological knowledge.
Following the idea to use gene expression monitoring for dis-
ease classiﬁcation and patient stratiﬁcation Laifenfeld et al. have
extended this approach to develop predictive biomarkers that
identify likely responders for a targeted therapeutic based upon
mechanistic inferences from patient data.13 The strategy relies
upon the hypothesis that patient groups that exhibit either high
levels or low levels of a gene expression signature (‘signal
strength’)—linked to a biological perturbation, for example, the
activation of the therapeutic target—will more likely respond to
treatment with that targeted therapeutic. The substrate for the
strategy is a knowledge base that has stored gene expression signa-
tures for over 2000 biological perturbations from peer-reviewed
publications. Each of these mechanisms can represent a potential
driver of disease. Patient stratiﬁcation by signal strength allows
identiﬁcation of those mechanisms that are most strongly or
weakly activated in different subsets of heterogeneous patients
and can be used in this way to identify subset most likely to re-
spond to a molecular-targeted treatment.
In a case study Laifenfeld et al. presented a classiﬁer to predict
response to a TNF targeted therapy inﬂiximab for ulcerative colitis
and veriﬁed it against a test set of patients where clinical outcomes
are unknown.13 The classiﬁer, a 256-gene signature is reﬂecting
the strength of TNF signalling coded by the individual levels of
TNF pathway activation (see Fig. 5). The ﬁgure reﬂects that patients
with lower levels of TNF pathway activation are more likely to re-
spond to inﬂiximab.
Causal reasoning. Similar to the approach applied by Laifenfeld
et al.13 causal reasoning algorithms attempt to predict causal driv-
ers of diseases or drug action on the molecular level. In order to
provide a detailed molecular hypothesis to explain the measured
Figure 3. Pathway of mTor signalling pathway with genes differentially expressed in old versus young mapped onto it (up-pregulated genes in red; down-regulated genes in
green). Several changes within the cell are not regulated on the gene expression level and are thus ‘invisible’ in a transcriptomics study: often enzymatic action is controlled
by, for example, phosphorylation or activation and/or deactivation by a metabolite or by a second messenger like cAMP or Ca2+.
Figure 4. Genes distinguishing ALL from AML. The 50 genes most predictive in the
ALL–AML class distinction are shown. Each row corresponds to a gene, with the
columns corresponding to expression levels in different samples. The top panel
shows genes highly expressed in ALL, the bottom panel shows genes more highly
expressed in AML (Fig. taken from 12).
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potent and selective diacylglycerol acyltransferase 1 (DGAT1)
inhibitor Enayetalla et al. applied a causal reasoning engine
(CRE).14 The CRE utilizes the microarray transcriptomic data from
rats treated with a DGAT1 inhibitor and causal statements derived
from the biomedical literature to infer upstream molecular events
driving these transcriptional changes. The inferred upstream
events (also called hypotheses) have been aggregated into biolog-
ical models using a set of analytical tools that allow for evaluation
and integration of the hypotheses in context of their supporting
evidence.
Mapping of drug and disease signatures. As mentioned above fol-
lowing the systems biology paradigm a complex disease is not seen
as a failure of a single gene or target, but is viewed as a conse-
quence of disease-perturbed networks characterized by a speciﬁc
disease ‘signature’. The objective of a successful drug treatment
would then be the reversal of the disease signature to normal. By
making use of novel non-parametric genome-wide metrics it has
been possible to ‘connect’ drugs, genes and diseases by simply
comparing the corresponding gene-expression signatures. As a
consequence, several approaches have been proposed to exploit
the massive amount of publicly available gene-expression data
for computational ‘drug re-purposing’ by using a ‘guilt-by-associa-
tion’ approach (i.e., if two drugs elicit a ‘similar’ transcriptional re-
sponse then they could share a therapeutic application) or by
measuring the extent of ‘anti-similarity’ between drug- and dis-
ease-signature (i.e., if a drug is able to revert a phenotype signature
then it could be able to ‘revert the phenotype’ as well). A review on
this topic has been compiled by Iorio et al.22
Such an approach has been performed by Kunkel et al. to devel-
op a potential therapy for skeletal muscle atrophy.23 Two sets of
differentially expressed genes have been derived from the analysis
of transcriptomics data taken from human and mouse muscle un-
Figure 5. Stratiﬁcation of diseased training set patients and healthy controls by their levels of TNF signaling pathway strength. Patients that respond to inﬂiximab are shown
in green, non-responders in black, and healthy controls in grey. Patients with lower levels of TNF pathway activation were more likely to respond to inﬂiximab (Fig. modiﬁed
from 13).
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used these two gene-lists to search the connectivity map (CMAP)
database. CMAP is a large collection of gene expression data fol-
lowing treatment by drugs and tool compounds.24 The query sys-
tem returned ursolic acid—a component of apple peal—with a
gene expression list opposite of those of the disease condition
(see Fig. 6). It was then experimentally veriﬁed that ursolic acid re-
duced muscle atrophy and stimulated muscle hypertrophy in mice.
Moreover, they observed additional effects on the characteristics of
muscle following treatment with ursolic acid, including reductions
in adiposity, fasting blood glucose, plasma cholesterol and triglyc-
erides. These ﬁndings suggest a potential use in muscle atrophy
and other metabolic myopathies.
Network inference. Not always signalling pathways or regulatory
networks are sufﬁciently known to allow for a meaningful gene-set
enrichment analysis or mapping of regulated genes onto pathway
maps. In this case, regulators or regulatory networks have to be de-
rived from the primary ‘omics’ data. Network reconstruction can be
achieved, for example, by identifying correlations in expressedFigure 6. Identiﬁcation of ursolic acid by matching of mRNA expression signatures.
To develop a potential therapy for skeletal muscle atrophy the two unbiased mRNA
expression signatures of muscle atrophy—resulting from fasting and spinal cord
injury—have been used to query the Connectivity Map, which singled out ursolic
acid as a compound whose signature was opposite to those of atrophy-inducing
stresses. A natural compound enriched in apples, ursolic acid reduced muscle
atrophy and stimulated muscle hypertrophy in mice (Fig. taken from 23).genes, using a number of methods including those based on infor-
mation theory, Bayesian models and regression models.18
In an attempt to identify additional type-2 diabetes (T2D)
genes, Taneera et al. recently analyzed the gene expression in hu-
man islets using a systems genetics approach.25 Human islets have
been characterized from healthy and T2D patients by performing
cDNA microarray and GWAS in addition to functional characteriza-
tion (insulin response to glucose and glycemic control by HbA1c)
from the same individuals. Using 48 genes located near T2D risk
variants, the authors identiﬁed gene co-expression and protein–
protein interaction networks that were strongly associated with is-
let insulin secretion and HbA1c. The network data was integrated
to form a list of putative T2D genes based on diverse criteria from
different subanalyses. The resulting list of potential T2D genes
highlights several candidate genes that might affect islet function.
The study thus sheds some light into mechanisms impairing islet
function and increasing the risk for T2D. In addition, several
known, e.g. GLP1R and KCNJ11 (Kir6.2 channel), but also promising
novel targets for a therapeutic treatment of T2D have been identi-
ﬁed (e.g., GPR120).
Counterparts to the top-down approaches are the bottom-up
methodologies. Here, the modeler starts with individual compo-
nents with well described properties and assembles them into a
network with the goal to then describe or simulate the dynamic
properties of the resulting system.
Depending on the detail and wealth of information available
different routes can be taken. If the information on the components
is rich (i.e., all interaction partners are known in molecular detail
and all interactions and their kinetic parameters are available)
molecular mechanistic models can be built. These will be discussed
in the next section. If the knowledge about the kinetics in the sys-
tem is sparse a number of other methodologies is available as will
be exempliﬁed in the section on logic-based models. In cases
where molecular details are not known or of lower interest the
dynamics of general physiological parameters (e.g., blood glucose
levels, insulin secretion from the pancreas) can be modeled. This
will be covered in the section on physiological models.
Molecular mechanistic models. In contrast to the network-based
approaches that help to gain deeper understanding of huge
amounts of data (e.g., ‘omics’ data) molecular mechanistic models
are designed to paint a predictive and dynamic picture of a biolog-
ical system of a smaller scale (e.g., a single signaling or metabolic
pathway, Fig. 7). Therefore, each reaction in the network is repre-
sented by a rate equation (ordinary differential equation = ODE)
for which all rate constants need to be known or estimated. If a
reaction follows a ﬁrst order mass action mechanism only one rate
constant constant is required. However, some biochemical reac-
tions have a rather complex mechanism and the number of kinetic
Figure 7. Mechanistic models attempt to copy nature by generating computational representations of biological processes (e.g., a molecular pathway or a physiological
system). They translate a pictorial representation into mathematical equations. These can be used for the computational simulation of the time courses of all elements in the
system following a perturbation (e.g., drug treatment).
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(e.g., the equations for the active Na+/K+ transport involve 13
parameters26). If the values have been experimentally determined
in the scientiﬁc community they often can be retrieved from the
literature or specialized databases (e.g., BRENDA27 and SABIO-
RK28). In addition to these parameters also the concentrations of
all components (e.g., metabolites, receptors, enzymes) in the initial
state of the system need to be known or estimated as starting point
of the simulation. In any case, these parameters (kinetic parame-
ters, concentrations of components) have to be ﬁtted to the exper-
imental time-course data of the speciﬁc cellular or physiological
system that is analyzed. Such a detailed molecular-mechanistic
model can then be used to simulate the dynamic behavior of the
system. This is done by employing well established numerical
ODE solvers which are part of modeling-software. The power of
ODE based models is that they quantitatively predict the time
course for each component in the system over the simulation per-
iod. Even for those components for which experimental data is not
readily or only sparsely available (e.g., intermediate metabolites or
second messengers), estimations for their quantitative and dy-
namic behavior can be derived from such a simulation.
The increasing number of published molecular-mechanistic
models requires the setup of on-line repositories for these data.
Over the last years several projects have established platforms that
allow browsing and retrieving ODE based models, usually in stan-
dardized ﬁle formats (e.g., SBML or CellML). Well known reposito-
ries are, for example, BioModels,29 CellML,30 JWS Online,31 VCell32
and ModelDB.33
Molecular mechanistic models have a comparatively long tradi-
tion in biological research. For example, already in 1952 Hodgkin
and Huxley published the ground-breaking simulations of the
membrane potential of the squid giant nerve axon.34 This type of
electrophysiological modeling inspired the modeling of the pro-
cesses in cardiac cells that are responsible for the rhythmic con-
traction of the heart. A review by Noble et al. lists more than 100
heart cell models published between 1962 and 2011.3 Such models
are of high interest in pharmaceutical research for prediction of
cardiac safety since they allow simulating desired and unwanted
drug effects on the action potential of the cardiomyocyte. A prom-
inent example is a potential drug side effect of the elongation of
the QT interval in the electrocardiogram that can lead to life-
threatening arrhythmias. Since the block of the hERG potassium
channel (KCNH2) can cause this QT elongation the 50% inhibitoryconcentration (IC50) of a drug candidate on the hERG channel is of-
ten used as a marker for the risk of arrhythmias. Since hERG is not
the only ion channel whose modiﬁcation can change the QT inter-
val the predictive power of the hERG IC50 is only limited. Mirams
et al. showed that mathematical models in conjunction with data
on additional ion channels can provide much better predictors
for the risk of arrhythmias than the IC50 of hERG alone (Fig. 8).35
This example highlights how mathematical models can help to im-
prove cardiac safety in drug discovery.
Molecular mechanistic models can be applied for identiﬁcation
and/or validation of novel drug target by simulating the expected
effect of a pharmacological intervention on a cellular system. The
effect of drugs may be described by adding a drug binding event
to its particular target to the model or by simply changing the va-
lue of those parameters that represent the biological activity of the
drug target. For example, the activation of a receptor can be simu-
lated by increasing the value of the parameter(s) that determine
the activity of the receptor. The inhibition of an enzyme is ex-
pressed through the decrease of the rate constant of the corre-
sponding enzyme. But not only the effects of existing drugs can
be investigated, it is also possible to design ‘virtual’ drugs with
completely new properties (new target, new binding properties
to a receptor etc.) and to test the effect on a system readout of
interest (e.g., amount of second messenger or cell cycle progres-
sion). These results then can help to design the blueprint for the
desired drug proﬁle that can guide drug discovery.
At Sanoﬁ, aiming for the discovery of novel targets increasing
the glucose-dependent insulin secretion, we have established a
mathematical model of the pancreatic beta cell. The ‘virtual pan-
creatic beta-cell’ has been generated by capturing all relevant pro-
cesses in this cell type by combining three published models
describing elements in the control of glucose-triggered insulin
secretion in the beta-cell (GPCR/cAMP signaling, b-cell electro-
physiology and calcium handling, insulin granule exocytosis).36
The resulting model contains numerous enzymes, transporters
and ion-channels involved in glucose stimulated insulin secretion.
Figure 9 shows an example of a simulation reﬂecting the predicted
insulin secretion after stimulation by two important insulin secret-
agogues, the sulfonylurea Glimiperide and the incretin GLP1. Sulfo-
nylureas (like Glimiperide) are an important class of oral drugs in
the treatment of early diabetes since they increase insulin secre-
tion after a meal. They act by closing an ATP sensitive potassium
channel (K-ATP channel) and this effect can be simulated by
Figure 8. Simulation of the changes in action potential duration under increasing concentrations of verapamil. In the left panel only the effect of a hERG block was considered
while the right panel shows the effect of verapamil when considering a hERG, Na and CaL block. The arrows indicate the effect on the action potential of increasing drug
concentration. This simulation shows that the effect of a hERG block on the action potential viewed in isolation can be misleading. Also the effects on other ion channels need
to be considered (Fig. from Mirams et al.35).
Figure 9. Simulation of the effect of Glimiperide and GLP1 on insulin secretion in the ‘virtual pancreatic b-cell’.36 Simulated were experiments of the perfused isolated rat
pancreas where a drug was applied at 3 min and the glucose concentration in the perfusate was increased from 5.6 to 16.7 mM at 12 min. The effect of Glimiperide was
modeled by reducing the conductance of the K-ATP channel by 75%, the effect of GLP1 by increasing the activity of the GLP1-receptor. In agreement with experimental data,
Glimiperide directly triggers insulin secretion even at low glucose levels, whereas GLP1 only acts at high glucose-levels by improving glucose-dependent insulin secretion.
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An important but unwanted side effect of sulfonylureas is that they
trigger insulin secretion at low glucose levels (i.e., under fasting
conditions). This can result in severe hypoglycemia (below normal
glucose levels). As shown in the left panel in Figure 9 this effect is
also seen in the simulation. On the other hand, GLP1 only enhances
insulin secretion at high glucose levels, thereby avoiding the risk of
hypoglycemia. Therefore, GLP1-receptor agonists should have a
better safety proﬁle in diabetes treatment. The simulation of the
GLP1 effect on the insulin secretion rate is shown in the right panel
in Figure 9. It correctly captures the improvement of the glucose-
dependent insulin secretion in presence of the GLP1 agonist. The
‘virtual pancreatic b-cell’ is currently used to predict the best drug
targets or target combinations for increasing the glucose-depen-
dent insulin secretion. Therefore, a sensitivity analysis is per-
formed to identify the most sensitive ‘screws’ in the system
connected to an improvement in insulin secretion.
Receptor tyrosine kinases are a family of receptors that attract
high interest in drug development. Since this class includes a num-
ber of growth factor receptors that play a role in the development
of cancer mathematical models of the downstream signaling path-
ways are highly relevant in the ﬁeld of oncology.
An elaborate model of epidermal growth factor receptor (EGF-
receptor) signaling had been designed by Chen, Schoeberl, Jasper
and co-workers to investigate the importance of the four members
of the EGF-receptor family (ErbB1-4).37 Since these members of the
EGF-receptor family form homo- and heterodimers (each havingindividual properties) combinatorial complexity is added to the
system. A version of this model that focused on the activation of
AKT—also known as protein kinase B (PKB)—was then used to iden-
tify the member of the EGF-receptor family that was the most
effective target for drug development.39 Until then the develop-
ment of therapeutic agents had focused on the receptor forms
ErbB1 and ErbB2. However, a sensitivity analysis performed with
this model could show that AKT activation was most sensitive to
an intervention at the ErbB3 form of the receptor family. This led
to the development of the ErbB3 speciﬁc antibody MM-121 that
is active in cancers with ligand-dependent receptor activation.38,39
This drug is now in clinical development.
Logic-based models. ODE based models require the complete
knowledge of the parameters used in the system, but often this
is incomplete and no reliable estimates can be made for the un-
known variables. However, even pathways or networks for which
no kinetic parameters are known can be used for valuable systems
analysis. In many cases the literature provides qualitative or half-
quantitative statements on an interaction between biological com-
ponents (e.g., receptor A activates kinase B—but time course and
quantity of the activation are unknown). Such data can be handled,
for example, in logic-based modeling approaches.40 A common
type of logic applied here is the Boolean logic. For each node (com-
ponent) in the network only two states are possible (e.g., ‘on’ or
‘off’) and the vertices (interactions) are causal relationships (e.g.,
‘if A is on then B is off’). Since nodes can have more than one input
logical rules are put in place to ensure that for each input combina-
Figure 10. The glucose insulin system model by Dalla Man et al.48 Figure A shows the pictorial layout of the physiological components in the model. Figure B presents
simulations of the plasma glucose and serum insulin levels over the course of a full day with 3 meals at 8, 12 and 20 h in an average normal individual and an average T2D
patient. The deregulation of the glucose insulin system in the disease is clearly visible.
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AND B is on then C is on’). An input (e.g., receptors A and C are
set to ‘on’) into such a Boolean network can then be propagated
in discrete time steps. Mutations or inhibition of components can
be modeled by removing the corresponding node or vertex from
the network. The methodology and biological applications are dis-
cussed, for example, in the reviews by Bornholdt or Morris and co-
workers.40,41
An example of Boolean network modeling has recently been
presented by Saez-Rodriguez et al.42 This group used a literature
based Boolean prior knowledge network of immediate-early sig-
naling in liver cells and trained it on biochemical data obtained
from hepatocytes and four hepatic cancer cell lines under various
treatments. The models generated by the ﬁt differed between the
cell types by the absence or presence of edges. Therefore, this study
uncovered differences in the wiring of the growth factor signaling
network between normal hepatocytes and transformed cells. Such
knowledge can be an important contribution to understanding
these types of cancer and to develop a suitable and effective ther-
apy. In addition the study was able to identify an off-target effect of
an IKK inhibitor on Jak2, based on the discrepancy between the
model and the phosphoproteomics data.
Physiological models. Biological systems need not always be pre-
sented on the level of molecular detail. A different approach is ta-
ken by physiological models. Like molecular mechanistic models
they are ODE based and can present the dynamics of a system.
But instead of focusing on individual enzymes, receptors etc. they
try to model a physiological aspect of a whole organism. For exam-
ple, this can be the secretion of insulin from the pancreas or the up-
take of glucose from the blood stream into peripheral tissues.
One class of physiological models, the so-called ‘minimal mod-
els’, is designed to describe the measurements of a speciﬁc type of
physiological or clinical experiment and connect these data to a
small set of physiological parameters of interest.43 Usually, these
models are not intended to run forward simulations to predict
measurements but they are used in the opposite (diagnostic)
way: using mathematical optimization algorithms the model is ﬁt-
ted to measured data in order to determine the values of the mod-
els parameter set. An example for this is the application of
mathematical models in the oral glucose tolerance test (OGTT).
In this test a patient ingests a deﬁned amount of glucose. After-
wards, the time course of blood glucose and insulin levels is mea-
sured. Minimal models now can be ﬁtted to these time courses to
yield indices for the ability of the pancreas to release insulin upon aglucose stimulus (‘beta-cell responsivity’) and the ability of periph-
eral tissues to remove glucose from the blood stream upon an insu-
lin stimulus (‘insulin sensitivity’).44 In order to produce robust and
precise parameter estimates minimal models need to contain only
a small number of parameters and components. If the design of the
model is too complex determination of parameters by the optimi-
zation algorithm can become problematic (the parameters are
‘non-identiﬁable’).
Consequently, minimal models can be seen rather as diagnostic
than predictive tools. In our example the minimal models can help
to investigate if a diabetic patient has decreased beta-cell respon-
sivity or decreased insulin sensitivity.
Minimal models can also be applied to long-term disease pro-
gression. An example is the mechanism-based disease progression
model by de Winter et al.45 The model describes the progressive
loss of b-cell function and insulin sensitivity in Type 2 Diabetes
Mellitus. By ﬁtting this model to the data of the treatment arms
of a 52 week clinical study it was able to describe the different ef-
fect of three drugs on the model parameters affecting disease pro-
gression. But of course, the model can also be used for forward
simulation of disease progression, for example, to check what ef-
fects an improvement of insulin sensitivity has compared to an
improvement of b-cell function on the clinical endpoint.
The so-called ‘maximal models’ are comprehensive descriptions
attempting to fully implement the body of information available
for a system. Because of the comparatively high number of param-
eters these models are usually not completely identiﬁable. As a
consequence, parameter values need to be drawn from various dif-
ferent experimental sources or through expensive and complex
experimental approaches from single patients. As a result the max-
imal model often represents an ‘average patient/system’ and is
used for systems simulation.
To give an example, in 2008 such a mathematical model of type
1 diabetes was accepted by the FDA as a substitute for preclinical
animal trials in artiﬁcial pancreas studies.46,47 The model captures
the glucose-insulin system and describes all major physiological
processes involved in plasma glucose homeostasis (glucose stimu-
lated insulin secretion in the pancreas, insulin stimulated glucose
uptake in peripheral tissues, glucose absorption from the intes-
tines, glucose production in the liver etc.).48 A layout of the model
is shown in Figure 10. The parameters of this model have been ob-
tained not only by following the serum insulin and plasma glucose
dynamics but also by extensive validation against various glucose
ﬂuxes obtained from 204 normal individuals who underwent a tri-
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tained for type 2 diabetic individuals. The simulator allows the sci-
entist to follow glucose and insulin levels during the course of a
day with varying meal schedules. Also the effects of a virtual drug
(e.g., a drug that improves insulin secretion in a diabetic individ-
ual) can be simulated. This can be done by changing those param-
eters in the model that are hypothesized to be affected by the drug
of interest. For an anti-diabetic drug in the glucose-insulin model
this could for, example, be the parameters that describe insulin
sensitivity or insulin secretion. Thus, this type of mathematical
model can help to ﬁnd those drug proﬁles that are most promising
in treating a disease effectively. In addition, they can be used to
predict the clinical efﬁcacy of drugs in virtual patients and to select
the most-promising drug candidate. Obviously, physiological mod-
els have a great potential in the design and support of clinical trials.
For example, they can help to narrow the dose range that needs to
be tested or to devise the best time points to take clinical measure-
ments. To aid drug development several commercial companies
now offer physiological models and services in this area (e.g., Bayer
Technology Services, Entelos and Rosa & Co).49–51
So far, we have discussed molecular mechanistic models and
physiological models separately. However, in drug discovery and
pharmacology it can be useful to merge these approaches. In a re-
cent article Iyengar et al. outlined this strategy that they named
enhanced pharmacodynamic (ePD) model.52 As an illustration they
presented an example from oncology: a mechanistic description of
the EGFR signaling pathway was combined with a more physiolog-
ical description on the effect of certain cell cycle factors on prolif-
eration and tumor growth. Since the mechanistic part in this model
could describe genomic and epigenetic alterations in individual pa-
tients the authors could predict the patient response on the level of
tumor growth to a treatment with an anticancer drug. This exam-
ple points out how ePD models could generate impact in personal-
ized medicine.
In conclusion, over the last years we have seen a paradigm shift
in how we view biology. Instead of focusing on isolated compo-
nents we now turn our attention to the properties of a biological
system as a whole. In this holistic view a certain biological prop-
erty is not necessarily caused by a single gene or protein but by
the sometimes complex interplay of components in a network. Of
course, this ‘systems view’ has also an impact on drug develop-
ment. Drug candidates discovered—following the traditional tar-
get-centric approach—often failed in clinical trials, as the
observed drug potency in in vitro assay systems or animal models
often did not translate in sufﬁcient efﬁcacy in humans. Expecta-
tions are high that a systems approach will lead to a more success-
ful discovery of novel therapies. Technical advances, especially the
advent of ‘omics’ technologies and the increased capabilities of
computers, have made it possible to investigate biological systems
under the new paradigm. This digest reﬂects the current state of
the systems biology ﬁeld with respect to the impact in drug devel-
opment. A number of examples show that systems approaches can
be successful in various areas like target identiﬁcation, patient
stratiﬁcation, drug repurposing, simulation of drug effects and clin-
ical trial design. Even though systems biology is an evolving disci-
pline and is only starting to show its impact it obviously has a huge
potential. Systems approaches are already increasingly employed
to answer biological questions. However, so far the high expecta-
tions have only been met in part and more years of research will
be required to unleash the full potential of systems biology.References and notes
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